REGULATORY

Pharmas Present 9 Requests on Drug Pricing, Tax to LDP Study Group

November 20, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Major Japanese pharma industry organizations on November 19 put forward nine requests on drug pricing and taxation reforms to a study group of the ruling Liberal Democratic Party, with a special focus on its opposition to annual price revisions. At…

To read the full story

Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
Pharma Leaders Rev Up Lobbying Campaigns ahead of Year-End Budget, Tax Debates
November 18, 2015

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…